The global inhalation CDMO industry is expected to expand at a CAGR of 5.7% in the forecast period 2024 to 2034. The market value is projected to increase from USD 8,639.1 million in 2024 to USD 14,863.6 million in 2034.
| Attributes | Key Insights |
|---|---|
| Base Value, 2023 | USD 8,144.2 million |
| Estimated Global Inhalation CDMO Market Size (2024E) | USD 8,639.1 million |
| Forecast Inhalation CDMO Market Value (2034F) | USD 14,863.6 million |
| Value-based CAGR (2024 to 2034) | 5.7% |
The pharmaceutical landscape is undergoing a transformative phase marked by continual innovations in inhalation drug delivery systems, constituting a pivotal driver for the contract development and manufacturing organization (CDMO) market. This evolution encompasses a spectrum of advanced technologies, emphasizing dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers.
As respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) become increasingly prevalent, the demand for efficacious and patient-friendly inhalation therapies escalates. Consequently, pharmaceutical companies are propelled to seek the expertise of specialized CDMOs to navigate the intricacies of these evolving delivery systems.
Formulation development, analytical testing, process optimization, and the production of inhalable medicinal products are the services provided by inhalation CDMOs. They could also help patients navigate the legal and regulatory procedures for developing respiratory drugs.
The expansion of the inhalation CDMO market is facilitated by advancements in inhalation technology, including the creation of unique medication formulations and inventive inhaler devices. Companies in this industry constantly invest in research & development to be on the cutting edge of technological advancements.
The inhalation CDMO market is expanding internationally, with firms offering their services to customers in several geographical areas. Pharmaceutical firms and inhalation CDMOs are increasingly forming partnerships and collaborations to pool resources and expertise.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global inhalation CDMO market recorded a historical CAGR of 4.0% from 2019 to 2023. The increasing prevalence of asthma and COPD drives the incidence of associated respiratory diseases.
In recent years, this has led to a surging demand for efficient respiratory care, including using respiratory inhaler devices. Healthcare professionals are increasingly inclined to adopt inhaler devices to deliver drugs directly to patients' respiratory tracts to ensure minimal wastage of drugs and to increase their efficacy.
The inhalation CDMO market experienced a notable impact from the escalating prevalence of asthma and chronic obstructive pulmonary disease (COPD). The rising incidence of these respiratory conditions has propelled the demand for inhaler devices, becoming a central driver in shaping the market dynamics.
The increasing prevalence of asthma and COPD has led to a growing patient population requiring long-term management and treatment. As a result, there is a heightened need for effective and convenient drug delivery systems, with inhaler devices emerging as a cornerstone in the therapeutic arsenal for these respiratory disorders.
The adoption of newly launched nebulizers with quick drug delivery inhalers would aid demand. In addition, a top-end technological assessment with greater accuracy is gaining traction among the population, further spurring revenue growth for the market.
The relentless pace of technological advancement is a driving force fueling the demand for respiratory inhaler devices and shaping the landscape of the respiratory healthcare market. Technical assessment plays a pivotal role in enhancing the capabilities and functionalities of inhaler devices.
The symbiotic relationship between technology and respiratory care drives the market toward innovative solutions. These would help offer improved patient outcomes, increased treatment adherence, and enhanced disease management.
The table below shows the estimated growth rates of the top five countries. China, Japan, and Spain are set to record higher CAGRs of 10.8%, 4.9%, and 3.8%, respectively, through 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 2.6% |
| China | 10.8% |
| Japan | 4.9% |
| Germany | 2.3% |
| Spain | 3.8% |
The United States dominated the global market and held a 33.1% market share in 2023. The United States is expected to exhibit a CAGR of 2.6% throughout the forecast period, driven by factors like:
The high prevalence of respiratory disorders such as asthma and COPD in the United States is a significant driver for the inhalation CDMO market. The demand for innovative inhalation therapies is surging, ultimately driving the growth of CDMOs in the United States.
In 2023, China held a dominant share of 7.7% in East Asia’s market. The market is expected to surge with a CAGR of 10.8% from 2024 to 2034. Some of the key drivers/trends include:
China faces a rising prevalence of respiratory disorders, including air pollution-related issues and an increasing number of smokers. This creates a substantial demand for advanced inhalation therapies, presenting an opportunity for CDMOs to cater to the growing healthcare needs in China.
China's pharmaceutical market is rapidly expanding, driven by a rising aging population, increased healthcare awareness, and high disposable income. This growth creates opportunities for CDMOs to collaborate with local and international pharmaceutical companies seeking inhalation drug development services.
Germany is expected to surge at a CAGR of 2.3% during the forecast period. This can be attributed to factors like:
Germany is a pharmaceutical hub with a strong emphasis on research and development activities. The country's well-established pharmaceutical industry demands specialized CDMOs, particularly those offering inhalation drug development expertise.
Germany's central location in Europe is a strategic base for companies that serve Europe’s pharmaceutical market. Inhalation CDMOs can leverage this location to establish a presence and cater to the diverse needs of the pharmaceutical industry.
Japan is set to surge at a CAGR of 4.9% between 2024 and 2034. Factors driving the market growth include:
In Japan, there is a high frequency of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), which drives up demand for inhalation treatments. As a result, inhalation CDMOs now have the chance to work with pharmaceutical firms to develop and produce respiratory medicinal products.
Japan has a solid pharmaceutical regulation system in place. Operating in Japan, inhalation CDMOs must navigate and abide by the rules established by the Pharmaceuticals and Medical Devices Agency (PMDA). Comprehending and obeying these rules is essential to developing and effectively launching new products in the market.
Japan is renowned for its technological breakthroughs. The country’s inventive research and development in inhalation medication delivery methods and technologies can benefit inhalation CDMOs operating nationwide. Being at the forefront of these developments enables companies to provide their clients with state-of-the-art solutions.
Over the forecast period, demand for inhalation CDMO in Spain is expected to rise at a CAGR of 3.8%. This growth projection can be attributed to several key factors:
Spain is a vital country in the global pharmaceuticals market. Spain-based inhalation CDMOs can expand their offerings to serve clients abroad or collaborate with multinational pharmaceutical firms. Incorporating this integration with the global market can yield supplementary growth prospects.
The aging population of Spain is driving up demand for healthcare services and pushing the inhalation CDMO market. The elderly are more likely to suffer from respiratory disorders, which makes effective inhalation therapy necessary. By creating specialized respiratory therapies, inhalation CDMOs can help satisfy these healthcare demands.
For inhalation CDMOs, it is crucial to consider Spain’s market trends and cultural preferences. Inhalable medicine products can succeed more in Spain’s market if their formulations and delivery methods are customized to suit regional tastes and medical standards.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The below section shows the commercial segment dominating by scale of operation. It is expected to surge at a CAGR of 6.3% by 2034. Based on product, the API segment is anticipated to rise at a 6.0% CAGR by 2034.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Commercial (Scale of Operation) | 6.3% |
| Formulation Development (Services) | 4.5% |
| API (Product) | 6.0% |
| Medium (Company Size) | 3.6% |
Collaborations and acquisitions are common growth strategies that leading companies employ in the inhalation CDMO market. They aim to enhance their capabilities, expand their service offerings, and stay competitive in the dynamic landscape.
For instance
| Attribute | Details |
|---|---|
| Estimated Market Size (2024) | USD 8,639.1 million |
| Forecast Market Value (2034) | USD 14,863.6 million |
| Anticipated Growth Rate (2024 to 2034) | 5.7% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; East Asia; South Asia and Pacific; Western Europe; Eastern Europe; Middle East and Africa |
| Key Countries Covered | United States, Canada, Mexico, Brazil, Chile, China, Japan, South Korea, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, BENELUX, Poland, Hungary, Romania, India, ASEAN Countries, Australia and New Zealand, GCC Countries, South Africa, and Türkiye |
| Key Market Segments Covered | Service, Product, Company Size, Scale of Operation, and Region |
| Key Companies Profiled | Recipharm AB; AptarGroup, Inc.; Hovione; Vectura Group Ltd; Nemera; Kindeva; H&T Presspart; Sanner GmbH; Stevanato Group; Medspray; ICONOVO AB; Lonza; Gerresheimer AG; Catalent; Patheon N.V. (Thermo Fisher Scientific, Inc.); Lubrizol Life Science; Enteris BioPharma; Cambrex Corporation; INKE; Piramal Pharma Limited; Lupin |
| Report Coverage | Market Forecast, Competition Intelligence, Drivers, Restraints, Opportunities, Trends Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
The global market was valued at USD 8,144.2 million in 2023.
The market is set to reach a valuation of USD 14,863.6 million by 2034.
Demand for inhalation CDMO increased at a 5.7% CAGR from 2019 to 2023.
The global market is projected to reach USD 8,639.1 million by 2024.
The United States accounted for a 33.1% share of the global market in 2023.
Germany held around 2.3% market share in 2023.
| Estimated Market Value (2024) | USD 74,998.1 million |
|---|---|
| Projected Market Size (2034) | USD 124,532.4 million |
| Market Value CAGR (2024 to 2034) | 5.2% |
| Estimated Market Size, 2024 | USD 24,027.9 million |
|---|---|
| Projected Market Size, 2034 | USD 41,938.9 million |
| Value-based CAGR (2024 to 2034) | 5.8% |
| Market Value (2023) | USD 22.5 billion |
|---|---|
| Market Expected Value (2033) | USD 39.4 billion |
| Market Projected CAGR (2023 to 2033) | 5.7% |
| Market Estimated Size (2023) | USD 48.09 billion |
|---|---|
| Market Forecasted Size (2033) | USD 89.43 billion |
| Market CAGR (2023 to 2033) | 6.4% |
Explore Healthcare Services Insights
View Reports
Inhalation CDMO Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
